Skip to main content
. 2022 Apr 27;28:859–874. doi: 10.1016/j.omtn.2022.04.012

Figure 2.

Figure 2

Intermittent LNP/arginase 1 mRNA administration leads to normal growth and survival of arginase-deficient mice

(A) Kaplan-Meier survival graph comparing arginase 1 wild type (Arg+/+, black line, n = 26) with untreated Arg1−/− (red line, n = 20), Arg1−/− mice treated with ARG1 mRNA formulated with LNP B (blue line, n = 25), and Arg1−/− mice treated with ARG1 mRNA and LNP A (green line, n = 12) (p < 0.0001 by Log rank test). (B) Weights of mouse groups demonstrate similar growth trajectory and weight comparing wild type (Arg1+/+, black line) with ARG1 mRNA LNP B formulation (blue line) (p = 0.999 at P13); however, differences exist compared with ARG1 mRNA LNP A formulation to Arg1−/− (green) (p = 0.009) and untreated Arg1−/− mice (red line) (p = 0.037 at P14). Physical size comparison of representative P14 (C), P18 (D), and P28 (E) LNP B ARG1 formulation with Arg1−/− mouse with an Arg1+/+ wild type. ARG1, arginase 1; Arg1, arginase 1, LNP, lipid nanoparticle. Data in (B) are represented as mean ± SD.